Solventum (NYSE:SOLV) Updates FY 2026 Earnings Guidance

Solventum (NYSE:SOLV) issued an update on its FY 2026 earnings guidance on Wednesday morning. The company provided earnings per share guidance of 7.100-7.200 for the period, compared to the consensus estimate of 6.550. The company issued revenue guidance of -.

Analysts Set New Price Targets

A number of research analysts have commented on the company. Weiss Ratings upgraded Solventum from a “hold (c)” rating to a “hold (c+)” rating in a research note on Friday, July 17th. Piper Sandler raised their target price on Solventum from $92.00 to $105.00 and gave the company an “overweight” rating in a report on Thursday. BMO Capital Markets began coverage on Solventum in a research report on Wednesday, July 8th. They set a “market perform” rating and a $81.00 price target on the stock. BTIG Research upped their price target on Solventum from $91.00 to $95.00 and gave the stock a “buy” rating in a report on Thursday. Finally, Wedbush upped their price target on Solventum from $94.00 to $101.00 and gave the stock an “outperform” rating in a report on Thursday. Seven investment analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $91.64.

Solventum Stock Up 0.0%

NYSE:SOLV traded up $0.04 on Friday, reaching $83.00. The stock had a trading volume of 1,076,505 shares, compared to its average volume of 1,415,262. The company has a current ratio of 1.07, a quick ratio of 0.75 and a debt-to-equity ratio of 0.96. The company has a 50-day moving average of $79.24 and a 200 day moving average of $74.38. The stock has a market cap of $14.37 billion, a P/E ratio of 10.15, a price-to-earnings-growth ratio of 1.35 and a beta of 0.60. Solventum has a 12-month low of $62.38 and a 12-month high of $90.00.

Solventum (NYSE:SOLV) last announced its earnings results on Wednesday, August 5th. The company reported $2.55 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.91 by $0.64. Solventum had a return on equity of 24.83% and a net margin of 17.26%.The business had revenue of $2.21 billion for the quarter, compared to analyst estimates of $2.15 billion. During the same period in the previous year, the company earned $1.69 earnings per share. The company’s revenue for the quarter was up 2.2% compared to the same quarter last year. Solventum has set its FY 2026 guidance at 7.100-7.200 EPS. On average, research analysts predict that Solventum will post 6.58 earnings per share for the current year.

Solventum News Summary

Here are the key news stories impacting Solventum this week:

• Positive Sentiment: Strong second-quarter results: Solventum reported adjusted EPS of $2.55, well above the $1.91 consensus estimate, while revenue of $2.21 billion also exceeded expectations. Organic sales grew 9.5%, indicating stronger underlying demand despite reported revenue growth of 2.2%. Solventum Reports Second Quarter 2026 Financial Results
• Positive Sentiment: Higher 2026 outlook: The company raised its full-year adjusted EPS guidance to $7.10-$7.20, above the approximately $6.55-$6.58 analyst expectation, and also increased guidance for organic sales growth and free cash flow. Solventum outlines HIS separation and raises 2026 EPS guide
• Positive Sentiment: Portfolio simplification and shareholder returns: Solventum plans to separate its Health Information Systems software business, allowing the remaining company to focus on MedTech while giving the software unit greater strategic flexibility. Buybacks, improved cash flow and the potential to unlock value are supporting the investment case. Solventum to hive off healthcare software business, raises profit forecast
• Positive Sentiment: Analyst support increased: Stifel, Wedbush and Piper Sandler raised their price targets to $100, $101 and $105, respectively. UBS also maintained a Buy rating, reinforcing expectations for additional upside from Solventum’s discounted valuation. UBS Remains a Buy on Solventum Corporation
• Neutral Sentiment: The planned separation could create value, but its benefits depend on successful execution, transaction timing and the ability of both businesses to operate efficiently as standalone companies. ERP-related timing benefits also make some of the quarter’s performance less representative of recurring results.

Hedge Funds Weigh In On Solventum

Several institutional investors and hedge funds have recently made changes to their positions in SOLV. T. Rowe Price Investment Management Inc. raised its stake in Solventum by 1,482.4% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 538 shares of the company’s stock valued at $43,000 after buying an additional 504 shares in the last quarter. Arax Advisory Partners acquired a new position in shares of Solventum in the 4th quarter worth approximately $40,000. Quarry LP acquired a new position in shares of Solventum in the 4th quarter worth approximately $103,000. Smartleaf Asset Management LLC increased its holdings in shares of Solventum by 23.6% in the 4th quarter. Smartleaf Asset Management LLC now owns 744 shares of the company’s stock valued at $60,000 after acquiring an additional 142 shares during the last quarter. Finally, Wilkerson Advisory Group LLC bought a new stake in shares of Solventum in the 4th quarter valued at approximately $68,000.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.